Press Release Archive NOX-E36

DISCLAIMER – IMPORTANT

The materials (including the press release, the information document and any other announcements and/or documents published by TME Pharma N.V.) do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United Kingdom, United States, Australia, Canada, or Japan or in any jurisdiction in which such offers or sales are unlawful. Any securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United Kingdom, United States, Australia, Canada, or Japan. Accordingly, unless registered or an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, exercised, transferred, delivered or distributed, directly or indirectly, in or into the United Kingdom, United States, Australia, Canada, or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. Any public offering of securities that would be made in the United States would be made by means of a prospectus that would be obtained from the company and would contain detailed information about the company and management, as well as financial statements. There will be no public offer of securities in the United States.

Basis of access
Access to electronic versions of these materials is being made available on this webpage for informational purposes only. Any person seeking access to this webpage represents and warrants that they are doing so for informational purposes only. Making press announcements and other documents available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy our securities. Further, it does not constitute a recommendation by us or any other party to sell or buy securities in TME PHARMA N.V.

Confirmation of understanding and acceptance of disclaimer and cookie
By clicking “AGREE” below, I represent and warrant that I have read and understood the disclaimer and basis of access set out above. I agree that the materials I receive are for my own use and will not be delivered, released, published or distributed to any person in any jurisdiction in which it would be unlawful to do so. I agree that a cookie will be stored on my computer that remembers my choice so that I will not need to be asked again.

The press releases published by TME Pharma (formerly NOXXON Pharma) and contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. TME Pharma disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed) | NOX-E36 (emapticap) | all

Date	Title	Download

2024, July 22 08:00 a.m.	TME Pharma announces strategic plan to externalize and monetize second clinical stage asset NOX-E36

2022, June 13 08:00 a.m.	NOXXON enters into collaboration with US National Cancer Institute to characterize effects of lead compounds on brain tumors

2019, February 01 8:00 a.m.	New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer

2015, April 23	Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

2014, June 02	NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

2014, April 04	NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

2013, July 24	NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

2012, June 19	NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

2010, July 7	NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36

2009, October 12	NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36

2009, June 8	NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer